MedTrace Logo

Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation

NCT07592923 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-18

No results posted yet for this study

Summary

This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.

Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.

Conditions

Interventions

PROCEDURE

MicroPulse transscleral cyclophotocoagulation

MicroPulse transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. Laser treatment will be applied transsclerally over the ciliary body using a power of 2500 mW. The treatment duration will be 100-120 seconds per hemifield, with 5-6 sweeps per hemifield.

PROCEDURE

Conventional transscleral cyclophotocoagulation

Conventional transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. Laser treatment will be applied transsclerally over the ciliary body using a power of 1.4-2.3 W, with an exposure duration of 1.4-1.8 seconds per coagulation spot.

Sponsors & Collaborators

  • Kazakh Eye Research Institute

    lead NETWORK

Principal Investigators

  • Assiya Shaikenova, MD · Kazakh Eye Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2026-08-18
Completion
2026-08-18

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07592923 on ClinicalTrials.gov